288 related articles for article (PubMed ID: 33631016)
41. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
42. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Baxter PA; Su JM; Onar-Thomas A; Billups CA; Li XN; Poussaint TY; Smith ER; Thompson P; Adesina A; Ansell P; Giranda V; Paulino A; Kilburn L; Quaddoumi I; Broniscer A; Blaney SM; Dunkel IJ; Fouladi M
Neuro Oncol; 2020 Jun; 22(6):875-885. PubMed ID: 32009149
[TBL] [Abstract][Full Text] [Related]
43. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Ullrich NJ; Prabhu SP; Packer RJ; Goldman S; Robison NJ; Allen JC; Viskochil DH; Gutmann DH; Perentesis JP; Korf BR; Fisher MJ; Kieran MW;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28833. PubMed ID: 33336845
[TBL] [Abstract][Full Text] [Related]
44. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
[TBL] [Abstract][Full Text] [Related]
45. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Fangusaro J; Gururangan S; Poussaint TY; McLendon RE; Onar-Thomas A; Warren KE; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Kun LE; Fouladi M
Cancer; 2013 Dec; 119(23):4180-7. PubMed ID: 24104527
[TBL] [Abstract][Full Text] [Related]
46. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
Robins HI; Chang SM; Prados MD; Yung WK; Hess K; Schiff D; Greenberg H; Fink K; Nicolas K; Kuhn JG; Cloughesy T; Junck L; Mehta M
Neuro Oncol; 2002 Apr; 4(2):109-14. PubMed ID: 11916502
[TBL] [Abstract][Full Text] [Related]
47. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
48. Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial.
Falsini B; Chiaretti A; Rizzo D; Piccardi M; Ruggiero A; Manni L; Soligo M; Dickmann A; Federici M; Salerni A; Timelli L; Guglielmi G; Lazzareschi I; Caldarelli M; Galli-Resta L; Colosimo C; Riccardi R
Brain; 2016 Feb; 139(Pt 2):404-14. PubMed ID: 26767384
[TBL] [Abstract][Full Text] [Related]
49. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
50. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
51. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study.
Jakacki RI; Bouffet E; Adamson PC; Pollack IF; Ingle AM; Voss SD; Blaney SM
Neuro Oncol; 2011 Aug; 13(8):910-5. PubMed ID: 21764821
[TBL] [Abstract][Full Text] [Related]
52. Outcomes of multidisciplinary management in pediatric low-grade gliomas.
Oh KS; Hung J; Robertson PL; Garton HJ; Muraszko KM; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e481-8. PubMed ID: 21470783
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
54. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
55. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Yalon M; Rood B; MacDonald TJ; McCowage G; Kane R; Constantini S; Packer RJ
Pediatr Blood Cancer; 2013 Jan; 60(1):71-6. PubMed ID: 22434731
[TBL] [Abstract][Full Text] [Related]
56. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
Puduvalli VK; Yung WK; Hess KR; Kuhn JG; Groves MD; Levin VA; Zwiebel J; Chang SM; Cloughesy TF; Junck L; Wen P; Lieberman F; Conrad CA; Gilbert MR; Meyers CA; Liu V; Mehta MP; Nicholas MK; Prados M;
J Clin Oncol; 2004 Nov; 22(21):4282-9. PubMed ID: 15514370
[TBL] [Abstract][Full Text] [Related]
57. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
58. Diencephalic syndrome as sign of tumor progression in a child with neurofibromatosis type 1 and optic pathway glioma: a case report.
Cavicchiolo ME; Opocher E; Daverio M; Bendini M; Viscardi E; Bisogno G; Perilongo G; Da Dalt L
Childs Nerv Syst; 2013 Oct; 29(10):1941-5. PubMed ID: 23615855
[TBL] [Abstract][Full Text] [Related]
59. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Warren KE; Gururangan S; Geyer JR; McLendon RE; Poussaint TY; Wallace D; Balis FM; Berg SL; Packer RJ; Goldman S; Minturn JE; Pollack IF; Boyett JM; Kun LE
J Neurooncol; 2012 Feb; 106(3):643-9. PubMed ID: 21968943
[TBL] [Abstract][Full Text] [Related]
60. Neurofibromatosis 1-associated optic pathway gliomas.
Shofty B; Ben Sira L; Constantini S
Childs Nerv Syst; 2020 Oct; 36(10):2351-2361. PubMed ID: 32524182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
